Company profile
Vireo Growth Inc.
OTC: VREOF · Healthcare · Drug Manufacturers - Specialty & Generic
#261 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
59CFH 66DQ 39GM 73SS 64
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), workforce scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$350.4M
Rev growth YoY (TTM)
+251.0%
Net income (FY)
-$68.1M
Employees
612
as of 2026-08-12
Market cap
$422.3M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$268.8M$268.8M2025
Net income-$68.1M-$68.1M2025
Operating income-$1.0M-$1.0M2025
Total assets$817.2M$817.2M2025
Liabilities$509.7M$509.7M2025
Equity$307.4M$307.4M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Retail100%
By geography
Not disclosed.
The read
What is Vireo Growth Inc.’s revenue?
Vireo Growth Inc. booked $268.8M in FY2025 revenue, growing 170% year over year — faster than most Healthcare companies we track, at a -25.3% net margin.
Peers · Healthcare
Vericel Corporation82B+Harrow Health, Inc.73BViemed Healthcare, Inc.75B+Ligand Pharmaceuticals Incorporated80B+CareRx Corporation71BIovance Biotherapeutics, Inc.59CNeighbors
Hennepin →Key facts
CEOJohn Mazarakis
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMinneapolis, MN
ExchangeOTC: VREOF
Employees612
IPO date2019-03-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.